Evolution of Facial Aesthetic Treatment Over Five or More Years
- 1 June 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 41 (6) , 693-701
Abstract
BACKGROUND Little information exists on how facial aesthetic treatments are incorporated into aesthetic regimens. OBJECTIVE Assess the evolution of facial aesthetic treatments in patients receiving long-term continuous onabotulinumtoxinA treatment. METHODS This international retrospective chart review included patients with ≥5 years of continuous onabotulinumtoxinA treatments including ≥1 glabellar lines treatment/year. Charts were reviewed for facial areas treated, number of treatments, doses/treatment visit, concomitant aesthetic procedures, and onabotulinumtoxinA-related adverse events. RESULTS Data were collected from 5,112 onabotulinumtoxinA treatment sessions for 194 patients over an average of 9.1 years. Dosing was relatively stable over time; however, interinjection intervals increased. Glabellar lines' treatment temporally preceded crow's feet lines and forehead lines' treatment. A majority of patients (85%) also received treatment with fillers. Cumulative increases in onabotulinumtoxinA treatments occurred over time and by facial area corresponding with increases in treatments with injectable fillers, energy-based devices, and prescription topical creams. The longer the patients were treated, the younger they perceived themselves to look. Rates of adverse events were low. CONCLUSION OnabotulinumtoxinA treatment evolved over time, coinciding with growth of the facial aesthetics market. Additional treatment modalities were added as complements to onabotulinumtoxinA. Long-term continuous onabotulinumtoxinA injections are an important component of contemporary facial aesthetic treatment regimens.Keywords
This publication has 22 references indexed in Scilit:
- Patient Satisfaction and Safety With Aesthetic OnabotulinumtoxinA After At Least 5 YearsDermatologic Surgery, 2015
- Lower-face and neck antiaging treatment and prevention using onabotulinumtoxin A: the 2010 multidisciplinary French consensus - part 2Journal of Cosmetic Dermatology, 2011
- Upper- and mid-face anti-aging treatment and prevention using onabotulinumtoxin A: the 2010 multidisciplinary French consensus - part 1Journal of Cosmetic Dermatology, 2011
- Dermal and epidermal remodeling using botulinum toxin type A for facial, nonreducible, hyperkinetic lines: two case studiesJournal of Cosmetic Dermatology, 2008
- Full-Face Carbon Dioxide Laser Resurfacing: A 10-Year Follow-Up Descriptive StudyPlastic and Reconstructive Surgery, 2008
- Botulinum Toxin Type A Treatment of Multiple Upper Facial SitesDermatologic Surgery, 2007
- Long-Term Effects of Botulinum Toxin Type A (Botox) on Facial LinesArchives of Facial Plastic Surgery, 2006
- Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Botulinum Toxin Type A for Patients with Glabellar LinesPlastic and Reconstructive Surgery, 2003
- A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar linesJournal of the American Academy of Dermatology, 2002
- Treatment of Glabellar Frown Lines with C. Botulinum‐A ExotoxinThe Journal of Dermatologic Surgery and Oncology, 1992